Analystreport

Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.25 pr

Satsuma Pharmaceuticals, Inc. - Common stock  (STSA) 
Last satsuma pharmaceuticals, inc. - common stock earnings: 3/10 04:01 pm Check Earnings Report